- Cancer Biology & Biomarkers
- Chromatography & Mass Spectrometry
- Contract Research, Clinical Trials and Outsourcing
- Drug Discovery
- Drug Targets
- Flow Cytometry
- Informatics & Lab Automation
- Ingredients, Excipients and Dosages
- Microbiology & RMMs
- NIR, PAT & QbD
- Raman Spectroscopy
- Screening, Assays & High-Content Analysis
- Thermal Processing
MacroGenics and Merck to study margetuximab and pembrolizumb in gastric cancer
22 October 2015 • Author: Victoria White
MacroGenics and Merck are to evaluate the combination of MacroGenics’ anti-HER2 product candidate, margetuximab, with Merck’s anti-PD-1 therapy, Keytruda (pembrolizumab), in patients with advanced gastric cancer.
Margetuximab is an Fc-optimized monoclonal antibody that targets the human epidermal growth factor receptor 2, or HER2, which is an antigen critical for the growth of many types of tumours, including breast and gastroesophageal cancers. Keytruda is a humanised monoclonal antibody that blocks the interaction between PD-1 and its ligands, PD-L1 and PD-L2.
“The combination of our proprietary Fc-optimised anti-HER2 antibody, with expected enhanced immune-mediated killing properties, and the anti-PD-1 antibody Keytruda, is intended to exploit potentially complementary biology,” said Scott Koenig, M.D., Ph.D., President and CEO of MacroGenics. “Treatment options for patients with advanced HER2-positive gastric cancer are extremely limited. The combination of mechanisms engaged by margetuximab and Keytruda could provide an important alternative for patients who do not respond to currently available regimens.”
MacroGenics expects to start enrolling patients early next year
“Today, there is a great opportunity and need to bring forward new scientific breakthroughs for the treatment of gastric cancer,” said Dr Eric Rubin, vice president and therapeutic area head, oncology early-stage development, Merck Research Laboratories. “Evaluating the potential of combination therapies through strategic collaborations in difficult-to-treat tumour types continues to be an important part of our immuno-oncology clinical development programme for Keytruda.”
The Phase 1b/2 trial will be conducted in two parts. The Phase 1b portion is designed to determine the safety and tolerability of margetuximab and Keytruda in patients with advanced gastric cancer, while the Phase 2 portion will evaluate the anti-tumour activity of margetuximab and Keytruda in patients with advanced HER2-positive gastric cancer. Trial startup activities are underway and MacroGenics expects to begin enrolling patients by the first quarter of 2016. The agreement includes a provision where the parties may extend the collaboration to include a potential Phase 3 clinical trial.
ABB Analytical Measurement ACD/Labs ADInstruments Ltd Advanced Analytical Technologies GmbH Analytik Jena AG Astell Scientific Ltd B&W Tek Bachem AG Bibby Scientific Limited Bio-Rad Laboratories BioNavis Ltd Biopharma Group Black Swan Analysis Limited Butterworth Laboratories Ltd CAPSUGEL NV Charles Ischi AG | Kraemer Elektronik Cherwell Laboratories CI Precision Cobalt Light Systems Coulter Partners CPC Biotech srl Dassault Systèmes BIOVIA DiscoverX Edinburgh Instruments Enterprise System Partners (ESP) Eurofins BioPharma Product Testing EUROGENTEC F.P.S. Food and Pharma Systems Srl GE Analytical Instruments IDBS JEOL Europe Kaiser Optical Systems Inc. L.B. Bohle Maschinen + Verfahren GmbH Lab M Ltd. LabWare Linkam Scientific Instruments Limited Lonza MA Business Metrohm Molins Technologies Multicore Dynamics Ltd Nanosurf New England Biolabs, Inc. Ocean Optics Panasonic Biomedical Sales Europe B.V. Peak Scientific ReAgent Russell Finex Limited Source BioScience Takara Clontech Tornado Spectral Systems Tuttnauer Viavi Solutions, Inc Watson-Marlow Fluid Technology Group Wickham Laboratories Limited Xylem Analytics YMC Europe GmbH Yusen Logistics